Zhejiang Provincial People's Hospital, affiliated with Hangzhou Medical College, Hangzhou, Zhejiang Province, China.
Aesthet Surg J. 2021 Feb 12;41(3):344-355. doi: 10.1093/asj/sjaa036.
Blindness is a rare but catastrophic complication of facial hyaluronic acid (HA) injection. Although various means to rescue visual impairment have been employed, no consensus regarding effective treatment has yet been reached. We organized a multidisciplinary team to address this emergency situation by means of endovascular hyaluronidase application.
The aim of this study was to investigate the direct delivery of hyaluronidase to ophthalmic artery occlusion through endovascular cannulation to resolve HA-induced blindness.
Four patients with visual impairments caused by HA filler embolization were subjected to sequential treatments. Through superselective angiography, a microcatheter was introduced along a guidewire from the femoral artery to the ophthalmic artery to directly deliver hyaluronidase to the HA embolism. The safety and efficiency of this treatment were systematically analyzed.
Selective cerebral angiography demonstrated that the endovascular application of hyaluronidase significantly alleviated occlusion in 3 patients. One patient showed slight visual improvement, whereas the other patients showed no improvement in their visual function during a follow-up period of more than 3 months. One patient suffered from cerebral infarction in the left middle cerebral artery during the intervention surgery. Moreover, 2 patients showed multiple lacunar cerebral infarctions after the operation, whereas none exhibited symptoms of hemiplegia during follow-up.
Although the endovascular application of hyaluronidase could partially recanalize the occluded branches of the ophthalmic artery, it had limited effects on restoring vision. Considering the risks of vascular intervention surgery, this approach should be considered with caution.
面部透明质酸(HA)注射后失明是一种罕见但灾难性的并发症。尽管已经采用了各种方法来挽救视力损伤,但尚未达成有效的治疗共识。我们组织了一个多学科团队,通过血管内透明质酸酶应用来解决这种紧急情况。
本研究旨在通过血管内插管将透明质酸酶直接输送到眼动脉阻塞部位,以解决由 HA 填充剂栓塞引起的失明。
对 4 例因 HA 填充物栓塞导致视力受损的患者进行连续治疗。通过超选择性血管造影,将微导管沿导丝从股动脉插入到眼动脉,以直接将透明质酸酶输送到 HA 栓塞部位。系统分析了这种治疗的安全性和有效性。
选择性脑血管造影显示,血管内应用透明质酸酶可显著缓解 3 例患者的血管阻塞。1 例患者的视力略有改善,而其他患者在 3 个月以上的随访期间视力功能无改善。1 例患者在介入手术中发生左侧大脑中动脉脑梗死。此外,2 例患者术后出现多发性腔隙性脑梗死,但在随访期间均无偏瘫症状。
尽管血管内应用透明质酸酶可部分再通眼动脉闭塞分支,但对恢复视力的效果有限。考虑到血管介入手术的风险,应谨慎采用这种方法。